Just published #OnlineFirst: A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in #Myeloid Neoplasms. @CCLRI @ClevelandClinic @leukaemielabor @LurieCancer @SylvesterCancer #MPN https://t.co/UQaQcZxjBz h
RT @yihong_guan: A four-year work through the collaboration with chemists, biologist and physician scientist. A Therapeutic Strategy for…
A four-year work through the collaboration with chemists, biologist and physician scientist. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms https://t.co/fU3BKHFuhF
RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…
RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…
RT @TheDoctorIsVin: A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context…
A clear mechanism for the observed mutual exclusivity of IDH & TET2 mutations, and a SL therapy in TET2 mutant context with TETi. Reversible effects on normal HSC (I’d love to dig into what’s happening there). Bravo to Jarek & team @ClevelandClinic